Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Adjuvant T-DM1 bij stadium I HER2-positieve borstkanker: resultaten na 5 jaar
nov 2024 | Borstkanker